Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Just caught up on Proto Labs' latest earnings and there's some genuinely insightful commentary from the analyst questions that deserves attention. The company posted solid Q4 numbers - $136.5M revenue (beat estimates by 5.4%), $0.44 adjusted EPS (27.9% beat), and margins finally turning positive at 5% versus negative 1.2% a year ago. Not bad at all.
What's interesting though is digging into what the analysts were actually probing at during the call. Greg Palm from Craig Hallum pressed management on whether that sequential revenue pattern meant demand was getting pulled forward. The CFO basically said Q4 had strong orders through year-end, but Q1 started soft as expected seasonally. Nothing too alarming there.
The more insightful questions came from Troy Jensen at Cantor Fitzgerald about why unique developers declined. CEO Suresh Krishna's response was telling - they're deliberately shifting focus from adding new developers to squeezing more revenue from existing customers and expanding wallet share. It's a strategic pivot toward quality over quantity. Jensen also dug into their defense supply chain involvement, and Krishna confirmed they're a preferred supplier for innovation-focused U.S. defense customers, riding that broader sector momentum without spelling out specific government contracts.
Brian Drab wanted clarity on injection molding growth prospects given their recent automation investments. Krishna highlighted the pivot toward production and flagged medical device programs as a potential growth driver, with pilot projects already in motion. That's worth monitoring.
Jim Ricchiuti's insightful take was asking whether sharing full-year guidance meant better demand visibility. The CFO's answer was refreshingly honest - it's about transparency during a transformation year, not necessarily that demand is more predictable. I appreciate that kind of candor.
Looking ahead, the real catalysts are going to be adoption rates for their new ProDesk customer experience tool, scaling those production programs with medical and aerospace customers post-certification, and how their European restructuring and India capability center buildout actually perform. The stock jumped from $52.48 to $66.51 post-earnings, so there's already momentum priced in. Whether that sustains depends on execution on these fronts. Definitely one to keep on the radar.